Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub

Core Insights - Defence Therapeutics Inc. has opened its first U.S. laboratory in the Boston-Cambridge area, marking its initial physical presence in the United States and reinforcing its commitment to advanced research and development in biotechnology [1][2][3] Company Expansion - The new laboratory is located at Cambridge Scientific Labs in Watertown, which will facilitate the development and optimization of the company's proprietary Accum® technology for antibody-drug conjugates (ADCs) [2] - Establishing a presence in the Boston-Cambridge area provides access to top-tier scientific resources and collaboration opportunities within the region's renowned biotech ecosystem [2] Strategic Importance - The CEO of Defence Therapeutics emphasized that this expansion is a significant milestone, positioning the company at the heart of the global biotech community and supporting its mission to advance the Accum® platform for next-generation ADCs [3] - The Cambridge Scientific Labs location will serve as a short-term base while the company evaluates options for a long-term facility in the area [2][3] Company Overview - Defence Therapeutics is a publicly-traded clinical-stage biotechnology company focused on developing next-generation radio-immuno-conjugate and ADC products using its proprietary ACCUM® technology, which enables precision delivery to target cells, enhancing efficacy against cancer [3]